Genetics of Common Endocrine Disease: The Present and the Future
Journal Title: | The journal of clinical endocrinology and metabolism 2016, Vol.101 (3), p.787-794 |
Main Author: | Goodarzi, Mark O |
Format: |
![]() |
Language: |
English |
Subjects: | |
Publisher: | United States: Endocrine Society |
ID: | ISSN: 0021-972X |
Link: | https://www.ncbi.nlm.nih.gov/pubmed/26908105 |
Zum Text: |
SendSend as email
Add to Book BagAdd to Book Bag
Staff View

recordid: | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4803177 |
title: | Genetics of Common Endocrine Disease: The Present and the Future |
format: | Article |
creator: |
|
subjects: |
|
ispartof: | The journal of clinical endocrinology and metabolism, 2016, Vol.101 (3), p.787-794 |
description: | Context: In honor of the 75th issue of the Journal of Clinical Endocrinology and Metabolism, the author was invited to present his perspectives on genetics in human endocrinology. This paper reviews what the field has achieved in the genetics of common endocrine disease, and offers predictions on where the field will move in the future and its impact on endocrine clinical practice. Evidence Acquisition: The October 2015 data release of the National Human Genome Research Institute-European Bioinformatics Institute (NHGRI-EBI) Catalog of Published Genome-wide Association Studies was queried regarding endocrinologic diseases and traits. PubMed searches were focused on genetic prediction of disease, genetic findings and drug targets, functional interrogation of genetic loci, use of genetics to subtype disease, missing heritability, systems genomics, and higher order chromatin structures as regulators of gene function. Evidence Synthesis: Nearly a quarter of genome wide association study findings concern endocrinologic diseases and traits. While these findings have not yet dramatically altered clinical care, genetics will have a major impact by providing the drug targets of tomorrow, facilitated by experimental and bioinformatic advances that will shorten the time from gene discovery to drug development. Use of genetic findings to subtype common endocrine disease will allow more precise prevention and treatment efforts. Future advances will allow us to move away from the common view of DNA as a string of letters, allowing exploration of higher order structure that likely explains much “missing heritability.” Conclusions: The future will see a greater role of genetics at the bedside, with genetic epidemiologic discoveries leading not only to new treatments of endocrine disease, but also helping us prescribe the right drug to the right patients by allowing subclassification of common heterogeneous endocrine conditions. Future technological breakthroughs will reveal the heritable mysteries hidden in chromatin structure, leading to a more complete characterization of heritability that will propel our ability to translate genetic findings into new preventions and treatments. |
language: | eng |
source: | |
identifier: | ISSN: 0021-972X |
fulltext: | no_fulltext |
issn: |
|
url: | Link |
@attributes |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PrimoNMBib |
|